![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, November 02, 2014 3:37:55 AM
Forbes Headline:
J&J Faces Potentially Disrupting Competition In Its Lucrative Glucose Monitoring Business From Tiny Diagnostics Outfit
http://www.forbes.com/sites/genemarcial/2013/03/11/jj-faces-potentially-disrupting-competition-in-its-lucrative-glucose-monitoring-business-from-tiny-diagnostics-outfit/
Taking the very "bullish" undertone of the Forbes article, when it was published, that since then DECN got 2 more victories versus J&J out of court.
And the conclusion from FORBES:
Decision Diagnostics could eventually gain a foothold in the high-margin market controlled by J&J and three other pharmaceutical giants. With Genstrip‘s approval, the product may attract other Big Pharma companies to either license it it or acquire all of Decision Diagnostics.
FEATURED ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM